Reimagining Medicine slide image

Reimagining Medicine

Company overview Financial review Innovation: Pipeline overview Financial performance Cardiovascular Immunology Conclusions Cardiovascular Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 43 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation